Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Jul 2020

Lin Yen-Ting, Tsai Tzu-Hsiu, Wu Shang-Gin, Liu Yi-Nan, Yu Chong-Jen, Shih Jin-Yuan

Abstract excerpt

OBJECTIVES: Osimertinib is active against epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC). However, its efficacy against complex EGFR mutations with T790M has not been evaluated. MATERIALS AND METHODS: In order to detect complex EGFR mutations, we consecutively sequenced cancer tissues by RNA reverse transcription polymerase chain reaction. Patients with advanced NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 32387812
DOI: 10.1016/j.lungcan.2020.04.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.PMID 32387812Read ↗

Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.Semantic proximity Read ↗

A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.Semantic proximity Read ↗

Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.Semantic proximity Read ↗

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative GroupSemantic proximity Read ↗

The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis.Semantic proximity Read ↗

Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.Semantic proximity Read ↗

Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Empirical Osimertinib as a Second-Line Treatment Is a Viable Option Following First- and Second-Generation TKI Therapy With Unknown EGFR Status in Treated Non-Small Cell Lung Cancer: A Retrospective Study.Semantic proximity Read ↗

Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.Semantic proximity Read ↗

Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation.Semantic proximity Read ↗

Osimertinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.